Aurora Cannabis (NASDAQ:ACB) stock is one of the most overlooked assets on the market; it’s as simple as that. Many investors are discouraged by Cannabis sector stocks after their abrupt drawdown during the past year. However, let me remind you of the market’s golden rule: “buy low, sell high.” If you haven’t already done so, consider buying the dip on ACB stock.
Aurora really is a “best-in-class” pick. First of all, the company exhibits the largest gross profit margins (53%) in the cannabis industry, suggesting that economics of scale is part of its furniture. Aurora’s achieved this feat by delivering a wide breadth of products spanning the medical and recreational markets. Furthermore, the company’s vertically integrated business model provides it with significant pricing and bargaining power. Its model flows from four mega-production facilities all the way to an online medical platform, enabling it to benefit from various synergies.
Another aspect to consider is Aurora’s growth in the international markets. The company’s an upstream market leader in countries like Israel, Germany, France, Poland and the United Kingdom. The firm’s global footprint lets it smooth out revenue by dodging single-jurisdiction regulatory surprises and coherent economic shocks.
Furthermore, BDSA forecasts Cannabis sales to expand by 22% for the full-year amid robust support from emerging markets. Aurora’s market stronghold suggests that its economic benefits from a rise in sales will likely exceed its peers, thus, proliferating its intrinsic value. As a matter of fact, the stock’s undervalued on a normalized basis. ACB stock is trading at a normalized price-sales discount of 37.35% and a price-book discount worth 24.86%, implying that market participants haven’t taken note of ACB’s latest financial performance.
I’m aware that the current market environment isn’t receptive to growth stocks, but Aurora has that ex-factor. Moreover, the stock’s underappreciated, with a relative strength index (RSI) reading of 44.52. Thus, I’m going for it on this one!
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
On the date of publication, Steve Booyens did not hold any position (either directly or indirectly) in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.